Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm
  • CME

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: August 11, 2020 Expiration: August 10, 2021
Start Activity
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Puma Biotechnology, Inc.
Seattle Genetics
Neelima Denduluri, MD, FASCO
Lee Schwartzberg, MD, FACP

Information on this Educational Activity

Faculty

Neelima Denduluri, MD, FASCO

Clinical Assistant Professor
Georgetown University
Washington, DC
Medical Oncologist
Virginia Cancer Specialists
Co-Director, Virginia Cancer Specialists Research Program
Associate Chair, US Oncology Breast Cancer Research Committee
Arlington, Virginia

Neelima Denduluri, MD, FASCO, has disclosed that she has received funds for research support paid to her institution from Amgen, AstraZeneca, Daiichi, Genentech, and Novartis.
Lee Schwartzberg, MD, FACP

Medical Director
West Cancer Center and Research Institute
Germantown, Tennessee
Chief Medical Director
One Oncology
Memphis, Tennessee

Lee Schwartzberg, MD, FACP, has disclosed that he has received funds for research support from Amgen; consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Genomic Health, Helsinn, Myriad, Napo, Spectrum, and Pfizer; and other financial or material support from Bayer.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 11, 2020, through August 10, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Introduction to HER2-Positive Breast Cancer: New Findings, Expanded Options, and an Evolving Treatment Paradigm (1 min)
  • CME

Loading...
View this brief introduction to the experts who will present clinical perspectives on leveraging HER2-targeted therapies for HER2-positive breast cancer.
Neelima Denduluri, MD, FASCO
Lee Schwartzberg, MD, FACP
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: August 11, 2020 Expiration: August 10, 2021

This program is divided into short segments that you can review from the Activity landing page.
PreviousNext

Related Content

On-demand webcast from a live Clinical Care Options (CCO) webinar with global expert perspectives on CDK4/6 inhibitors for early-stage HR+/HER2- breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 21, 2021 Expired: July 20, 2022

From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Allison Butts, PharmD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 20, 2021 Expired: July 19, 2022

Gain key clinical insights quickly with this short slideset from CCO on the latest data on treatment for patients with HR+/HER2- early breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: July 9, 2021

Experts assess recurrence risk and use CDK4/6 inhibitors for HR+/HER2- early breast cancer in this on-demand webcast from a live Clinical Care Options (CCO) webinar

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 9, 2021 Expired: July 8, 2022

Video Chapters


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Puma Biotechnology, Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue